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Background.Themajority of patients develop posttraumatic osteoarthritis within 15 years of anterior cruciate ligament (ACL) injury.
Inflammatory and chondrodegenerative biomarkers have been associated with both pain and the progression of osteoarthritis;
however, it remains unclear if preoperative biomarkers differ for patients with inferior postoperative outcomes.Hypothesis/Purpose.
The purpose of this pilot studywas to compare biomarkers collected on the day of ACL reconstruction between patientswith “good”
or “poor” 2-year postoperative outcomes. We hypothesized that inflammatory cytokines and chondrodegenerative biomarker
concentrations would be significantly greater in patients with poorer outcomes. Study Design. Prospective cohort design.Methods.
22 patients (9 females, 13 males; age = 19.5±4.1 years; BMI = 24.1±3.6 kg/m2) previously enrolled in a randomized trial evaluating
early anti-inflammatory treatment after ACL injury. Biomarkers of chondrodegeneration and inflammation were assessed from
synovial fluid (sf) samples collected on the day of ACL reconstruction. Participants completed Knee Injury and Osteoarthritis
Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) questionnaires two years following surgery.
Patients were then categorized based on whether their KOOS Quality of Life (QOL) score surpassed the Patient Acceptable
Symptom State (PASS) threshold of 62.5 points or the IKDC PASS threshold of 75.9 points. Results. Patients that failed to reach
the QOL PASS threshold after surgery (n = 6, 27%) had significantly greater sf interleukin-1 alpha (IL-1훼; p = 0.004), IL-1 receptor
antagonist (IL-1ra; p = 0.03), and matrix metalloproteinase-9 (MMP-9; p = 0.01) concentrations on the day of surgery. Patients
that failed to reach the IKDC PASS threshold (n = 9, 41%) had significantly greater sf IL-1훼 (p = 0.02). Conclusion. These pilot
data suggest that initial biochemical changes after injury may be an indicator of poor outcomes that are not mitigated by surgical
stabilization alone. Biological adjuvant treatment in addition to ACL reconstruction may be beneficial; however, these data should
be used for hypothesis generation and more definitive randomized clinical trials are necessary.
1. Introduction
Whether isolated or in concert with concomitant menis-
cal or articular cartilage injury, anterior cruciate ligament
(ACL) rupture initiates a cascade of cytokine and catabolic
enzyme activity [1–4]. Regardless of surgical or conservative
management, the majority of patients develop posttraumatic
osteoarthritis (PTOA) within 15 years of ACL injury [5–7].
In addition to magnetic resonance imaging (MRI) and/or
radiographic evidence of cartilage degeneration [8–11], the
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Table 1: Concomitant injuries and surgical treatments (n (%)) performed at the time of ACL reconstruction.
Not injured Injured, not treated Debrided Repaired
Meniscus
Medial 8 (36%) 0 (0%) 1 (5%) 13 (59%)
Lateral 8 (36%) 0 (0%) 3 (14%) 11 (50%)
Tibial Articular Cartilage
Medial 22 (100%) 0 (0%) 0 (0%) 0 (0%)
Lateral 22 (100%) 0 (0%) 0 (0%) 0 (0%)
Femoral Articular Cartilage
Medial 21 (95%) 1 (5%) 0 (0%) 0 (0%)
Lateral 22 (100%) 0 (0%) 0 (0%) 0 (0%)
onset of PTOA is associated with increased concentrations of
chondrodegenerative and inflammatory biomarkers [12, 13].
Increased biomarkers of cartilage turnover have not only
been reported as a late consequence of ACL injury, but
also been reported to be significantly elevated immediately
following ACL injury [2–4, 14].This may indicate chronically
increased cartilage turnover and a progressively destructive
process thatmay have long-term clinical consequences. How-
ever, while inflammatory and chondrodegenerative biomark-
ers are elevated in the period between ACL injury and recon-
struction [3, 4], there is a substantial knowledge gap with
regard to the role of preoperative biomarker concentrations
and their association with either successful or suboptimal cli-
nical outcomes.
One method to objectively quantify a successful outcome
is to determine whether a patient has achieved a Patient
Acceptable Symptom State (PASS) following surgery [15–18].
The PASS represents a threshold for a given postoperative
outcome score above which the patient is defined as having
a satisfactory outcome. Patients that fail to achieve the PASS
threshold are then considered to have a suboptimal postoper-
ative outcome.The purpose of this pilot study was to compare
biomarkers assessed from samples collected preoperatively
on the day of ACL reconstruction between patients with 2-
year postoperative patient-reported outcome scores above
and below previously established PASS thresholds [18]. We
hypothesized that synovial fluid and urine concentrations of
inflammatory cytokines and chondrodegenerative biomark-
ers would be significantly greater in patients with poorer
outcomes.
2. Methods
Participants included 22 patients (9 females, 13 males; age=
19.5 ± 4.1 years (mean ± standard deviation); BMI=
24.1 ± 3.6 kg/m2, Table 1) that had previously consented to
participate at one site of an IRB-approved, multicenter
prospective randomized clinical trial evaluating early anti-
inflammatory treatment after ACL injury (clinicaltrials.gov
ID: NCT01692756) [3]. At the time of enrollment, patients
with an isolated ACL injury between the ages of 14 and 32
with closed growth plates were included. Other inclusion
criteria included a normal contralateral knee, no history
of previous traumatic ipsilateral knee injury, and an ACL
injury that occurred during sports activity with no clinical
evidence of posterior cruciate ligament injury and with
no more than grade 1 medial or lateral collateral ligament
injury. Patients were excluded if the injury occurred more
than eight days prior to enrollment or they had a history
of previous ipsilateral knee surgery, a known allergy to
triamcinolone acetonide, intra-articular cortisone injection
into either knee within three months of injury, or a history
of any inflammatory disease or immunocompromise [3].
In the initial trial, biomarkers were assessed at three
time points prior to surgery to determine if early anti-in-
flammatory treatment could alter the expected progressive
increases in inflammatory and chondrodegenerative bio-
marker concentrations [3]. The three time points from the
initial study were (1) mean 4 days after injury, (2) mean
11 days after injury, and (3) the day of ACL reconstruction
(mean 37 days after injury). For the current study, we used
only biomarker data from samples acquired on the day of
ACL reconstruction to assess if inflammatory and chon-
drodegenerative biomarker concentrations differed between
those with good versus poor postoperative outcomes. In
original study, patient-reported outcomes on the day of
surgery did not differ between patients treated with preoper-
ative intra-articular corticosteroid and the placebo group. In
addition, the surgical intervention and postoperative rehabil-
itation andmedications did not differ between groups and no
between-group differences were noted in either postoperative
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Quality of Life scores (QOL; corticosteroid = 72.7 ± 16.1 ver-
sus placebo = 67.8 ± 31.1, p = 0.82) or International Knee
Documentation Committee scores (IKDC; corticosteroid =
74.8 ± 12.9 versus placebo = 71.2 ± 12.3, p = 0.46). As
such, we therefore pooled data for all patients for the current
analysis.
Knee aspiration was performed aseptically at the time
of surgery via a superolateral suprapatellar approach, and
intra-articular placement was confirmed using the “squish”
test [19]. Patients were fasting as both urine and synovial
fluid (sf) samples were collected on the morning of surgery.
Synovial fluid and urine samples were spun at 3500 RPM
for 10 minutes and the supernatant aliquoted according to
an allotment protocol. Once all samples were collected they
were shipped to the Duke University biomarker laboratory
(VBK/JLH) for analysis [3].
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A number of chondrodegenerative biomarkers and in-
flammatory cytokines were assessed using previously de-
scribed methods (Table 2) [3, 4]. All biomarker concentra-
tions were assessed from synovial fluid samples with the
exception of CTX-II which was assessed in both the syn-
ovial fluid (CTX-II) and urine (uCTX-II). Urinary CTX-II
was normalized to creatinine concentration (ng/mmol) [13].
Biomarker variability, linear range of standard, and need
for repeat were carefully assessed. Several commercially-
available ELISA kits provided controls, which were used with
every run to confirm that values were within the acceptable
range according to the manufacturer and to assess interassay
(plate to plate) variability. In addition, synovial fluid from
a human subject with knee OA that had previously been
aliquoted and frozen at −80∘C was used as the control for
all assays. A fresh aliquot of this control synovial fluid
was thawed and used on every plate to calculate intra-
and interassay variance of the assay each day that analyses
were performed. Due to limited sf sample volume available,
samples were run in singlicate; however, all standards and
controls were run in duplicate and used to determine the
precision of the assay and to establish an acceptable control
range for the assay. The mean of the control sample for all
assays plus or minus two standard deviations was defined
as the acceptable control range. All control samples were
within the acceptable control range for all plates and assays.
Mean intra-assay coefficients of variation for each assay are
reported in Table 2. Mean interassay coefficients of variation
were all <15% with the exception of IL-1훼 and IL-1훽. The
manufacturer reported that interassay CVs for these assays
are 6.6% and 6.4%, respectively; however due to the human
control SF sample having values at or below the level of
detection, this calculation was not possible. For values of IL-
1훼 and IL-1훽 that were below the lower limit of detection, 1/2
LLOD (lowest level of detection) was reported for statistical
purposes.
Patients were contacted two years after surgery to com-
plete standardized patient-reported outcomes, including
IKDC and KOOS Scores [18, 21–25].The volume of preopera-
tive bone bruises was calculated from each patient’s preop-
erative magnetic resonance imaging (MRI) scan using pre-
viously described methods [26]. MRIs were considered ade-
quate for inclusion if they included T2 or PD sequences in the
coronal, axial, and sagittal plane as well as slice thicknesses <
5mm. The bone bruise volumes in the medial tibial plateau,
medial femoral condyle, lateral tibial plateau, and lateral
femoral condyle were measured from the T2 or PD weighted
coronal images in a modification of Roemer and Bohndorf ’s
technique [26, 27]. Bone bruises volumes from each of the
four bony regions were then summed and expressed as the
total bone bruise volume (mm3) [26].
2.1. Statistical Analysis. Mann–Whitney U tests were per-
formed to determine if inflammatory cytokines and chon-
drodegenerative biomarkers assessed from samples collected
on the day of surgery (Table 2) differed from those with
either a good or poor outcome based on postoperative IKDC
and KOOS QOL scores. Due to the high number of IL-1훽
samples that were below the lower limits of detection (11/22,
50%), for this cytokine we also used Fisher Exact tests to
compare the prevalence of concentrations below the lower
limits of detection (LLOD) between groups. Patients were
categorized as having a good or poor outcome based on
whether they reported IKDC or KOOS QOL scores above
or below previously established Patient Acceptable Symptom
State (PASS) thresholds following ACL reconstruction of 62.5
points for KOOS QOL and 75.9 points for the IKDC [18]. As
the KOOS QOL and IKDCmay be assessing different aspects
of the patient’s outcome, separate analyses were run based on
the KOOS QOL PASS definition and IKDC PASS definition.
Cohen’s d effect sizes calculations were also performed in
order to identify potentially clinically-meaningful findings
within these pilot data, with d > 0.80 considered a large effect
size [28]. Analyses were performed using SPSS Statistics 24
(IBM, Armonk, NY) and Excel 2016 (Microsoft, Redmond,
WA) with p < 0.05 considered statistically significant. All
data and results are stored at the Department of Orthopaedic
Surgery and Sports Medicine at the University of Kentucky.
3. Results
At a mean follow-up of 2.4 years, 6/22 patients (27%) had
postoperative KOOS QOL scores below the PASS threshold
of 62.5 points (Table 3). Patients that failed to reach the QOL
PASS threshold had significantly greater sf IL-1훼 (p=0.004),
sf IL-1ra (p=0.02), and sf MMP-9 (p=0.01). While not sta-
tistically significant, markers of type I and type II collagen
breakdown (sf NTX-I [p=0.055] and uCTX-II [p=0.08])
tended to be greater for those that failed to reach the QOL
PASS threshold.Graft type, the prevalence ofmeniscus injury,
and bone bruise volumes did not differ between QOL PASS
groups (Table 3).
Nine of 22 patients (41%) failed to reach the IKDC
PASS threshold of 75.9 (Table 4). Patients that failed to
reach the IKDC PASS threshold had significantly greater
sf IL-1훼 (p=0.02). While not statistically significant, sf IL-
1ra (p=0.057), sf MMP-1 (p=0.10), and sf MMP-9 (p=0.10)
tended to be greater for those that failed to reach the IKDC
PASS threshold. No other biomarker differences were noted
between those that did or did not surpass the IKDC or
QOL PASS thresholds. Graft type, the prevalence of meniscus
injury, and bone bruise volumes did not differ between IKDC
PASS groups (Table 4).
4. Discussion
The purpose of this pilot study was to compare biomark-
ers assessed from samples collected on the day of ACL
reconstruction between patients with postoperative patient-
reported outcome scores above and below previously estab-
lished PASS thresholds [18]. We hypothesized that synovial
fluid and urinary concentrations of inflammatory cytokines
and chondrodegenerative biomarkers would be significantly
greater in patients with poorer outcomes, and our hypotheses
were, in part, supported by the current results.
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Table 3: Comparison of inflammatory cytokines and chondrodegenerative markers (mean ± standard deviation) evaluated on the day of
ACL reconstruction between patients with KOOS QOL scores above and below the PASS threshold of 62.5 points.
Biomarker < PASS ≥ PASS pa de
N 6 16 - -
Female/Male (n) 3/3 6/10 0.66 -
Steroid/Placebo (n) 4/2 12/4 > 0.99 -
Age (years) 18.0 ± 2.6 20.0 ± 4.5 0.42 -
BMI (kg/m2) 22.4 ± 2.9 24.8 ± 3.6 0.15 -
Graft (BTB/Hamstring) 5/1 13/3 > 0.99 -
Medial meniscus injury 5 9 0.35 -
Lateral meniscus injury 2 12 0.12 -
Bone bruise volume (mm3) 7.99 ± 8.93 11.07 ± 9.33 0.50 0.30
COMP (휇g/ml) 32.3 ± 12.5 39.3 ± 14.0 0.42 0.51
CTX-II (ng/ml) 1.57 ± 0.93 1.52 ± 1.97 0.38 0.03
uCTX-IId (휇g/mmol) 5.72 ± 4.86 2.42 ± 2.09 0.08 0.99
sGAG (휇g/ml) 190.9 ± 69.9 264.7 ± 168.3 0.83 0.49
IL-1𝛼 (pg/ml) 9.47 ± 7.65 2.21 ± 2.20 0.004 1.36
IL-1훽c (pg/ml) 0.11 ± 0.13 0.45 ± 1.48 0.76 0.26
IL-1ra (pg/ml) 2,593.2 ± 3,576.4 2,086.3 ± 5,507.0 0.03 0.10
MMP-1 (ng/ml) 640.07 ± 81.58 394.06 ± 667.06 0.27 0.35
MMP-3 (ng/ml) 4,017.2 ± 4,576.41 2,532.80 ± 3,066.43 0.56 0.43
MMP-9 (ng/ml) 30.99 ± 35.96 6.94 ± 10.30 0.01 1.07
NTX-I (nM BCE) 30.3 ± 7.9 22.7 ± 7.1 0.055 0.97
TSG-6 (U) 286.4 ± 165.7 260.1 ± 157.3 0.83 0.11
a Statistically significant differences denoted with bold and italics font.
b Number of patients in the corticosteroid or placebo group from the original randomized trial.
c There was also no difference in the number of samples below LLOD between groups.
< Pass=3/6 versus ≥ PASS=8/16, p > 0.99.
d u = urinary, the remaining biomarkers were measured in synovial fluid. Urinary CTX-II normalized to creatinine level (휇g/mmol).
e Cohen’s d effect sizes calculations were also performed in order to identify potentially clinically-meaningful findings within these pilot data, with d > 0.80
considered a large effect size.
The current pilot results support the previously described
cascade of increased IL-1훼 stimulating the production of
matrix metalloproteinases thereby reducing proteoglycan
content and altering cartilage mechanical properties. Previ-
ous studies have demonstrated that ACL injury triggers a
biochemical cascade that worsens over the first 4-6 weeks
after injury [2–4]. Inflammation is initiated early by the
injury-related hemarthrosis and subsequent intra-articular
pathogenic processes at the time of injury, including the
downregulation of proteoglycan synthesis and upregulation
of matrix metalloproteinases [29–31]. It is widely accepted
that IL-1 and IL-1ra are critical in the regulation of the
pathological processes involved in joint tissue breakdown
[32, 33]. Synovial fluid IL-1 levels are elevated in patients
with ACL rupture and correlate with severity of chondral
damage [34]. Synovial fluid levels of the chondroprotective
IL-1ra cytokine are reported to decrease significantly after
ACL injury, resulting in relatively unopposed activity of IL-
1 [1]. Additionally, levels of IL-1ra decrease as the severity of
chondral damage is increased [34]. The superficial cartilage
layers have been shown to bemore susceptible to IL-1 induced
damage than deeper layers in vitro [35]. Porcine cartilage
explants have been demonstrated to be more sensitive to the
chondrodegenerative effects of IL-1훼 than IL-1훽 [36].
The current pilot results suggest that initial biochemical
changes after injury may be prognostic of long-term conse-
quences of injury of the knee that are notmitigated by surgical
stabilization alone. Inflammatory cytokine and degradative
enzyme concentrations on the day of ACL reconstruction
have been previously shown to correlate with cartilage
changes onMRI during the first three years after surgery [37],
and the current results further demonstrate a connection
between cytokine and degradative enzyme concentrations
and the potential progression of posttraumatic OA. In the
current study, both IL-1훼 and MMP-9 concentrations on the
day of surgery were significantly higher for patients that
failed to postoperatively achieve the KOOS QOL-based PASS
compared to those with better clinical outcomes. In addition
to increased IL-1a and MMP-9 concentrations, biomarkers
of bone and cartilage turnover (sf NTX-I, d = 0.97 and
uCTX-II, d = 0.99) were also increased for patients that
failed to achieve KOOS QOL-based PASS. This overall state
of upregulated catabolism and inflammation may lead to
recurrent effusions and/or persistent synovitis which also
appears to potentially have long-term implications for knee
health.
In addition to playing a contributing role in the progres-
sion of structural posttraumatic OA changes [37], increased
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Table 4: Comparison of inflammatory cytokines and chondrodegenerative markers (mean ± standard deviation) evaluated on the day of
ACL reconstruction between patients with IKDC scores above and below the PASS threshold of 75.9 points.
Biomarker < PASS ≥ PASS pa de
N 9 13 - -
Female/Male (n) 5/4 4/9 0.38 -
Steroid/Placebob (n) 6/3 10/3 0.66 -
Age (years) 18.9 ± 3.5 19.9 ± 4.6 0.82 -
BMI (kg/m2) 24.1 ± 3.9 24.2 ± 3.5 0.84 -
Graft (BTB/Ham) 8/1 10/3 0.62 -
Medial meniscus injury 7 7 0.38 -
Lateral meniscus injury 4 7 > 0.99 -
Bone bruise volume (mm3) 9.19 ± 7.94 10.94 ± 10.18 0.67 0.17
COMP (휇g/ml) 30.9 ± 10.2 41.9 ± 14.3 0.10 0.81
CTX-II (ng/ml) 1.16 ± 0.72 1.79 ± 2.16 0.92 0.37
uCTX-IId (휇g/mmol) 3.92 ± 4.08 2.91 ± 2.77 0.62 0.30
sGAG (휇g/ml) 199.5 ± 70.1 275.8 ± 183.2 0.82 0.51
IL-1𝛼 (pg/ml) 5.48 ± 4.56 3.29 ± 5.80 0.02 0.41
IL-1훽c (pg/ml) 0.08 ± 0.09 0.55 ± 1.64 0.60 0.37
IL-1ra (pg/ml) 1,899.1 ± 3,014.8 2,621.5 ± 6,332.1 0.057 0.11
MMP-1 (ng/ml) 597.22 ± 689.63 366.96 ± 715.61 0.10 0.33
MMP-3 (ng/ml) 3,217.23 ± 4,074.67 2,744.09 ± 3,180.20 0.87 0.14
MMP-9 (ng/ml) 21.85 ± 31.59 7.71 ± 11.31 0.10 0.63
NTX-I (nM BCE) 26.6 ± 8.6 23.5 ± 7.5 0.33 0.40
TSG-6 (U) 260.9 ± 196.8 271.7 ± 129.3 0.53 0.40
a Statistically significant differences denoted with bold and italics font.
b Number of patients in the corticosteroid or placebo group from the original randomized trial.
c There was also no difference in the number of samples below LLOD between groups.
< Pass=5/9 ersus ≥ PASS=6/13, p > 0.99.
d u = urinary, the remaining biomarkers were measured in synovial fluid. Urinary CTX-II normalized to creatinine level (휇g/mmol).
e Cohen’s d effect sizes calculations were also performed in order to identify potentially clinically-meaningful findings within these pilot data, with d > 0.80
considered a large effect size.
inflammatory cytokine and degradative enzyme concentra-
tions on the day of ACL reconstruction also appear to affect
postoperative patient-reported outcomes. InOA knees, nerve
growth factor expression in the synovium has been shown
to modulate pain by increasing local nociceptor sensitization
[38, 39]. Nerve growth factor expression is increased in the
synovium of OA knees [40], and by regulating nerve growth
factor expression, proinflammatory cytokine IL-1 and other
degradative enzymes may play an integral role in modulating
knee pain [40]. While attention is given the potential role
of the innate immune response on cartilage degradation
and the progression of OA [41], it should be noted that,
after adjusting for age, peripheral cytokine concentrations
are similar between patients with knee OA and fibromyalgia
[42].Hypersensitivity and nociceptor sensitization secondary
to increased proinflammatory cytokine concentrations may
then explain the increased IL-1훼 and MMP-9 concentrations
for those that failed to achieve a Patient Acceptable Symptom
State in the current study.
Early anticatabolic and/or anti-inflammatory interven-
tions after ACL injury or reconstruction may need to be
further investigated as adjunctive treatment strategies to
mitigate both the structural changes and symptoms of post-
traumatic OA. CTX-II has been reported to be predictive
of OA progression based on both radiographic and arthro-
scopic evidence [43–45]. Particularly relevant to the current
results suggesting a link between CTX-II concentrations
and patient-reported outcomes, Ishijima et al. reported that
urinary CTX-II was associated with concurrent OA-related
pain [46].The association between CTX-II, pain, and inferior
outcomes may be tied to the combination of both changes to
the articular cartilage and to bone metabolism. Garnero et al.
first reported that urinary CTX-II concentrations in early OA
patients were predictive of bone marrow lesion progression
[47]. More recently, in a cluster analysis of a wide spectrum
of OA-related biomarkers, van Spil reported that CTX-II
tended to cluster with other biomarkers associated with
bone metabolism [48]. Bone marrow lesions are common
following ACL injury [26, 49], and many resolve over time
[50]. However, subjective symptoms of early OA are more
common six years after ACL reconstruction for those noted
to have local articular cartilage damage combined with bone
marrow lesions at the time of surgery [26]. The size and
progression of bone marrow lesions have been previously
linked to OA-related pain as the subchondral bone is rich
with nociceptors whereas the articular cartilage is not [51–
53]. Taken together with our data, links between CTX-II,
NTX-I, IL-1훼, pain, and both cartilage and bone metabolism
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may all contribute to KOOS QOL and IKDC outcomes at 2
years.
This study had several limitations. First and foremost, the
results of this preliminary work are based on a small sample
size and additional studies are necessary to confirm these
results. Second, some patients had received corticosteroid
injections prior to surgery which could have influenced
biomarker concentrations on the day of surgery. As men-
tioned previously, KOOSQOL and IKDC scores did not differ
between patients treated with preoperative intra-articular
corticosteroid and the placebo group, and the surgical inter-
vention and postoperative rehabilitation andmedications did
not differ between groups and no between-group differences
were noted in either postoperative KOOS QOL or IKDC
scores. Third, the prevalence of patients with postoperative
KOOS QOL and IKDC scores below the PASS threshold was
higher in the current study than those originally reported by
Muller et al. [18]. This may be due, in part, to the differences
in patient populations between the two studies. In the current
study, all patients were injured during athletic participation
with an average age at the time of surgery of 19.5 years
compared to 26.1 in the study by Muller et al. [18]. The
lingering effects of athletic injuries have been reported to
negatively impact quality of life years after competition has
ended, and both physical and mental aspects of function
are significantly lower in former collegiate athletes compared
to college attendees who did not participate in sport [54].
It remains unclear if the increased prevalence of patients
with inferior patient-reported outcomes in the current study
was perhaps due to the strict inclusion criteria of athletic
ACL injuries. Fourth, while inferior patient-reported out-
come scores have been associated with early OA changes,
postoperative imaging or biomarker evidence of OA will
be necessary to establish the potential connection between
biomarkers on the day of surgery, KOOS QOL, IKDC scores,
and evidence of structural features of knee OA. Finally,
future work may require more sensitive methods to quantify
synovial fluid IL-1훽 concentrations as 50% of the samples
in the current study had values below the lower limits of
detection.
In conclusion, the results of this preliminary investigation
demonstrated that higher inflammatory cytokine activity (IL-
1훼) and a trend towards greater bone and cartilage collagen
degradation (NTX-I and uCTX-II) at the time of surgery
were associated with failure to achieve an acceptable symp-
tom state two years after ACL reconstruction. These data sug-
gest that initial biochemical changes after injury may be pro-
gnostic of long-term consequences of ACL injury that are not
mitigated by surgical stabilization alone; however, due to the
small sample size these data should be used for hypothesis
generation and more definitive randomized clinical trials are
necessary.
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